AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma
Phase 2
Completed
- Conditions
- Cancer of Head and Neck
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 47
- Registration Number
- NCT00242749
- Locations
- 🇪🇸
Research Site, Santander, Spain
IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure
Phase 1
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00242788
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study
Phase 3
Completed
- Conditions
- NSCLC
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1692
- Registration Number
- NCT00242801
- Locations
- 🇻🇪
Research Site, Various Cities, Venezuela
An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)
Phase 4
Completed
- Conditions
- GERD
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2009-03-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 350
- Registration Number
- NCT00242736
- Locations
- 🇺🇸
Research Site, Norfolk, Virginia, United States
Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05)
Phase 2
Completed
- Conditions
- Bronchial Asthma
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00242307
- Locations
- 🇯🇵
Nycomed Japan and Mitsubishi Tanabe Pharma Corporation, Osaka, Japan
High Doses of Candesartan Cilexetil on the Reduction of Proteinuria
Phase 3
Completed
- Conditions
- Proteinuria
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2007-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 270
- Registration Number
- NCT00242346
- Locations
- 🇨🇦
Research Site, Saskatoon, Saskatchewan, Canada
MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults
Phase 4
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1900
- Registration Number
- NCT00242411
- Locations
- 🇳🇴
Research Site, Årnes, Norway
GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin
Phase 3
Terminated
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 370
- Registration Number
- NCT00242372
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119)
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 551
- Registration Number
- NCT00242320
- Locations
- 🇨🇳
Altana Pharma/Nycomed, Tau-Yuan, Taiwan
Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 570
- Registration Number
- NCT00242294
- Locations
- 🇯🇵
Nycomed Japan and Mitsubishi Tanabe Oharma Corporation, Osaka, Japan
© Copyright 2025. All Rights Reserved by MedPath